Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
16 results
D2.308 - Diet quality and intake behaviours among alpha-gal–positive patients at a specialized allergy clinic in Sri Lanka
D2.317 - “Cutaneous Anaphylaxis to Raw Egg White in a Patient with Established Oral Tolerance: Clinical Evidence Supporting the Dual-Allergen-Exposure Hypothesis”
D2.318 - Don`t miss the cannabis-associated food syndrome (CAFS)
D2.303 - The effect of extrusion on the in vivo allergenicity of pistachio and walnut in allergic children
D2.305 - Alpha-gal syndrome
D2.306 - From baked cookie to unheated milk: Desensitization in a high-risk cow’s milk protein allergy patient
D2.315 - Clinical Characteristics and Diagnostic Challenges in Pediatric Peanut and Tree Nut Allergies: The Impact of Unnecessary Elimination
D2.316 - Novel Homozygous Mutation in CARD11 gene Predisposing To Recurrent Infections and Atopies, and Response to Immunoglobulin therapy
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis
Download the app
The congress at your fingertips
Available on
Download